$ADCT News

ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC Says

ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty Amendments

ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

ADC Therapeutics (ADCT) Price Target Increased by 43.18% to 2.68

ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook

ADC Therapeutics S.A. Q2 2026 Earnings Call Summary

ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...

ADC Therapeutics Q2 Earnings Call Highlights

ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Q2 2026 Earnings Call Transcript

ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ADC Therapeutics Announces New Employee Inducement Grant